Adherence to monthly online self-assessments for short-term monitoring: a 1-year study in relapsing-remitting multiple sclerosis patients after start of disease modifying treatment
Authors Jongen PJ, Sanders E, Zwanikken C, Koeman J, Visser LH, Koopmans P, Lehnick D
Received 10 November 2012
Accepted for publication 29 January 2013
Published 9 April 2013 Volume 2013:7 Pages 293—300
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Peter Joseph Jongen,1 Evert Sanders,2 Cees Zwanikken,3 Jan Koeman,4 Leo H Visser,5 Petra Koopmans,6 Dirk Lehnick,7 OPTIVIT study group
1MS4 Research Institute, Nijmegen, 2Amphia Ziekenhuis, Breda, 3Maxima Medisch Centrum, Eindhoven, 4Admiraal de Ruyter Ziekenhuis, Vlissingen, 5St Elisabeth Ziekenhuis, Tilburg, 6Signidat, Groningen, The Netherlands; 7Nuvisan GmbH, Neu-Ulm, Germany
Background: The participation of neurologists and patients in studies on the effectiveness and safety of newly authorized drugs in multiple sclerosis (MS) is insufficient. Monthly online self-assessments using patient-reported outcomes may help in short-term monitoring of neurological changes and side effects.
Objective: Investigate in relapsing-remitting (RR) MS patients the adherence to monthly online self-assessments after the start of disease modifying treatment.
Methods: Observational study in 39 neurological departments in The Netherlands. Patients starting glatiramer acetate treatment were instructed to complete online the Modified Fatigue Impact Scale 5-item version and the 8-item Leeds Multiple Sclerosis Quality of Life scale every month during 1 year (T0 toT12).
Results: Sixty-three investigators included 163 analyzable patients. At T3, 148 (90.8%) patients had completed all questionnaires; at T6, 142 (87.1%); at T9, 133 (81.6%); and at T12, 123 (75.5%). Eight (4.9%) patients did not complete any questionnaire. Median values for inter-assessment intervals ranged from 32 to 34 days (first quartile [Q1] 30 days, third quartile [Q3] 41 days), and the final assessment was at 417 days (median: Q1 385 days, Q3 480 days). Forty-three (26.3%) patients completed the questionnaires at all time points (completion adherent) with their final assessment within 30 days after the scheduled T12 (interval adherent). Eighty (49.1%) patients were completion adherent, but not interval adherent. Forty (24.5%) patients were not completion adherent, as they discontinued assessments prematurely. Men were more interval adherent than women (47.5% vs 20.0%; P = 0.001).
Conclusion: The observation that three out of four (75.5%) RRMS patients completed two short questionnaires at all monthly time points during 1 year after the start of disease modifying treatment suggests that intensive online monitoring in this patient group is feasible. As only one in five (19.6%) patients adhered to the time intervals between self-assessments, measures are needed that improve the timely completion of questionnaires.
Keywords: effectiveness, glatiramer acetate, fatigue, health-related quality of life, MFIS-5, LMSQoL
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]